AMA
Grygiel-Górniak B, Shaikh O, Niranjan Kumar N, Heng Hsu S, Samborski W. Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients. Reumatologia/Rheumatology Supplements. 2021:252-259.
APA
Grygiel-Górniak, B., Shaikh, O., Niranjan Kumar, N., Heng Hsu, S., & Samborski, W. (2021). Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients. Reumatologia/Rheumatology Supplements, 252-259.
Chicago
Grygiel-Górniak, Bogna, Osama Shaikh, Nikita Niranjan Kumar, Shao Heng Hsu, and Włodzimierz Samborski. 2021. "Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients". Reumatologia/Rheumatology Supplements: 252-259.
Harvard
Grygiel-Górniak, B., Shaikh, O., Niranjan Kumar, N., Heng Hsu, S., and Samborski, W. (2021). Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients. Reumatologia/Rheumatology Supplements, pp.252-259.
MLA
Grygiel-Górniak, Bogna et al. "Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients." Reumatologia/Rheumatology Supplements, 2021, pp. 252-259.
Vancouver
Grygiel-Górniak B, Shaikh O, Niranjan Kumar N, Heng Hsu S, Samborski W. Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients. Reumatologia/Rheumatology Supplements. 2021:252-259.
